The intelligence terminal for pharma leaders

Pharma doesn’t need more information.It needs sharper signal.

Get Insites reads the global flow of pharma information and turns it into ranked opportunities for pharma leaders, with a sales copilot that tells you and your team where to act, who to approach and why now.

See plans and pricing

Updated as new developments break18 technologies in 5 segmentsFacts separated from inference

Opportunity feed Ranked by where to act first Sample from the live terminal

Act Now

Eli Lilly, $6.5bn Houston siteUtilities and cleanrooms. United States. Construction

85opportunity

High Potential

Merck, $2.9bn Pennsylvania expansionNewUtilities and vaccines. Investment announced

75opportunity

High Potential

Sanofi, EUR 2bn insulin projectNewCartridge fill-finish and devices. Germany

75opportunity

High Potential

Baxter, FDA warning letterNewEnvironmental monitoring and QC labs. United States

65opportunity

High Potential

Merck buys WuXi Irish vaccine plantNewRetrofit and requalification. $500M acquisition

60opportunity

Sales copilot: Sanofi Germany, injectable and sterile

Engage Sanofi's German engineering team now on cartridge fill-finish, inspection and pen assembly scope for the EUR 2bn programme, while specifications are still open.

Company names and brand assets belong to their respective owners and are shown for identification only. Examples drawn from public sources.

How every insight is built, in every cycle

18technologies mapped across 5 segments

4scores on every link: relevance, opportunity, urgency, confidence

6action classes, from Act Now to No Relevance

100%of relevant links get a sales copilot

The problem

Your team reads the headlines. The winners act on them first.

A new plant, an FDA warning letter or a technology transfer can mean a multi-million order for the right supplier. It usually arrives buried in hundreds of headlines, with no clue about which machines it needs or who decides.

A typical morning feed

Stocks to watch today: pharma, banks, metals noise
Prefillable glass syringes market to 2035 noise
Sanofi launches EUR 2bn insulin project in Germany signal
Drugmaker strikes $15bn licensing deal noise
Pharma tycoon steps back from family business noise
FDA warning letter: Baxter sampling could miss contamination signal
Single-use clamps market forecast to 2035 noise
Merck buys WuXi Biologics' Irish vaccine plant for $500M signal
FDA approves new oral solution for Sjogren's noise

Headlines paraphrased from public sources. Company and brand names belong to their respective owners.

Too much to read, too little to act on

In a typical cycle, fewer than one in five information snippets is a real development. Your BD team should not be the filter.

A headline never says which machine it needs

"New facility announced" does not tell you whether it is tablets, sterile fill-finish or utilities. Without that, you cannot prioritise.

Timing decides who gets the order

Utility and process packages are specified early. Find out at commissioning and the specification is already written around someone else.

How it works

From raw information to a next action in four steps

Every development is mapped against 18 pharma technologies and scored for relevance, opportunity, urgency and confidence.

Read

We scan global pharma, regulatory and trade information, including regional sources most teams never see.

Global + regionalsources scanned continuously

Filter

Duplicates, market-research adverts and off-topic stories are removed. What remains is a real development.

Under 1 in 5snippets kept as developments

Map and score

Each development is tested against every technology. If there is no logical link, it is tagged "probably no relevance".

18 × 4technologies × scores per development

Act

Every link gets a sales copilot: what to do, who to investigate, what to research next and why the timing matters.

1 copilotfor every relevant link

Inside the terminal

A sales copilot for every opportunity, not a report for the shelf

Open any development and see exactly how it affects your technology, what evidence supports it, and the specific next step for your team.

High PotentialInvestment, Capacity expansionNew

Sanofi launches a EUR 2bn project in Germany to boost EU insulin security

Relevance80

Opportunity75

Urgency50

Confidence55

What to do

Engage Sanofi's German engineering team now on cartridge fill-finish, inspection and pen assembly scope for the EUR 2bn programme.

Evidence

FACTEUR 2bn insulin supply project in Germany.

INFERENCEInsulin capacity typically spans cartridge fill-finish and pen assembly as well as drug substance.

Who to investigate

Sanofi Germany industrial affairs and engineering, and Sanofi's global insulin supply leadership.

Company names and brand assets belong to their respective owners and are shown for identification only. Examples drawn from public sources. Inferences are labelled as such.

Command centre

The headline signal of the cycle, KPI cards and exhibits that show where demand is building and in which stage.

Technology clusters

Pick your technology, from tablet compression to OT cybersecurity, and see every development ranked for it.

Opportunity matrix

Every development against every technology on one screen. Any cell opens its copilot in two clicks.

Latest insights

New developments are tagged as they arrive, so returning users see what changed first.

Share with your team

Send any development, copilot or exhibit to WhatsApp or email in one tap, ready to forward.

Full source registry

Every information snippet behind every insight, with its outlet and date, so your team can verify before outreach.

Coverage

18 technologies in 5 segments, each scored separately

The same development can be Act Now for utilities and irrelevant for capsules. Get Insites scores each technology on its own, so you only see what matters to your portfolio.

Oral and topical dosage4 technologies

Oral solid dosageCapsule processingOral liquidsOintment and cream

Sterile, biologics and advanced therapies5 technologies

Injectable and sterileVaccine manufacturingBiopharma and vaccine supportBiopharma and advanced therapiesCell and gene therapy

Packaging2 technologies

Packaging machineryPackaging materials

Facility, quality and compliance3 technologies

Utilities and environment controlLaboratory and analyticalValidation and compliance

Digital, service and sustainability4 technologies

Digital, PAT and automationOT cybersecurityLifecycle and aftermarketESG and sustainability

Every development, all 18 technologies

Each technology gets its own relevance, opportunity, urgency and confidence score, then an action class from Act Now to Probably No Relevance.

Who it's for

Built for pharma leaders who decide where to play and when to move

For leadership teams across pharma manufacturers, technology and equipment providers, CDMOs, EPCs and advisors.

CEOs, founders and MDs

See where capacity, capital and regulatory pressure are moving, and which markets deserve your next bet.

Sales and business development heads

Ranked opportunities with a copilot that says who to approach and why now, ready to hand to account owners.

Strategy and corporate development

Track greenfields, acquisitions, closures and partnerships to shape portfolio, M&A and market-entry decisions.

Marketing and product leaders

Know which technologies are gaining demand by region and stage, and build messaging and launches around it.

Operations, quality and projects

Follow FDA actions, remediation trends and new-build activity that shape your own compliance and capex priorities.

Investors, consultants and advisors

A structured view of who is building what, where and when, across global and regional markets.

Plans and pricing

Choose monthly flexibility or annual value

Every plan includes the full terminal. Pay monthly, or commit for a year and save up to 48%.

Single User

For a business development lead or founder tracking their own markets.

$142.50/month

Billed annually at $1,710

You save $1,350 a year (44%)

Full terminal access for 1 user
All 18 technologies
Sales copilot for every development
Opportunity matrix and source registry
WhatsApp and email sharing

Best value

Team, up to 5 users

For sales and BD teams covering several regions or product lines.

$390/month

Billed annually at $4,680

You save $4,320 a year (48%)

Works out to $78 per user per month

Full terminal access for up to 5 users
Everything in Single User
One view of opportunities across your team
Share copilots straight to account owners
Lowest cost per user

Enterprise and custom

For larger teams, or when you need intelligence built around your portfolio.

Tailored

Scoped to your markets, products and team size

More than 5 users
Customised trade terminal for your organisation
Custom research projects
Your segments, geographies and target accounts
Dedicated onboarding

Monthly and annual price comparison
Plan	Monthly plan	12 months, paid monthly	Annual plan	Effective per month, annual	You save with annual
Single User	$255	$3,060	$1,710	$142.50	$1,350 (44%)
Team, up to 5 users	$750	$9,000	$4,680	$390	$4,320 (48%)

All prices in US dollars. Taxes as applicable. Team monthly pricing works out to $150 per user per month; annual to $78.

Questions

What teams ask before they subscribe

Anything else? .

Where does the intelligence come from?

From global and regional pharma, regulatory, trade and business information sources. Every insight links back to its sources in the source registry, so your team can check the original before acting.

How are opportunities scored?

Each development is scored for relevance, opportunity, urgency and confidence against each of the 18 technologies, then classified from Act Now to Probably No Relevance. Facts from sources are labelled separately from our inferences.

How often are insights updated?

The terminal is refreshed as new developments are processed, and new items carry a New tag so you can see what changed since your last visit.

Can I share insights with colleagues outside my plan?

Yes. Any development, copilot or exhibit can be sent to WhatsApp or email as a ready-to-read summary.

What is the difference between monthly and annual?

The terminal is the same. Annual billing costs less: $1,710 a year instead of $3,060 for a single user, and $4,680 instead of $9,000 for a team of up to 5.

Are the companies shown partners of Get Insites?

No. Companies and brands appear because they feature in public information about pharma manufacturing. All names, logos and brand assets belong to their respective owners and are shown for identification only, without implying endorsement or affiliation.

Can you build a terminal around our products and markets?

Yes. The Enterprise and custom plan covers a customised trade terminal for your organisation and custom research projects scoped to your segments, geographies and target accounts.

See your next order before your competitors do

Book a 30-minute walkthrough of the live terminal with your own technologies, or start with a plan today.

Compare plans